The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.

Journal

Pharmacogenetics and genomics
ISSN: 1744-6880
Titre abrégé: Pharmacogenet Genomics
Pays: United States
ID NLM: 101231005

Informations de publication

Date de publication:
04 Oct 2024
Historique:
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: aheadofprint

Résumé

Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic associations with drug response, pharmacogenetic testing has not been widely implemented into clinical practice. Among the barriers to broad implementation are limited guidance for how to successfully integrate testing into clinical workflows and limited data on outcomes with pharmacogenetic implementation in clinical practice. The Pharmacogenomics Global Research Network Implementation Working Group seeks to engage institutions globally that have implemented pharmacogenetic testing into clinical practice or are in the process or planning stages of implementing testing to collectively disseminate data on implementation strategies, metrics, and health-related outcomes with the use of genotype-guided drug therapy to ultimately help advance pharmacogenetic implementation. This paper describes the goals, structure, and initial projects of the group in addition to implementation priorities across sites and future collaborative opportunities.

Identifiants

DOI: 10.1097/FPC.0000000000000547 PMID: 39485373
pubmed: 39485373
doi: 10.1097/FPC.0000000000000547
pii: 01213011-990000000-00073
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Références

The Pharmacogenomics Global Research Network. https://www.pgrn.org/. [Accessed 13 February 2024]
Clinical Pharmacogenetics Implementation Consortium Guidelines. https://cpicpgx.org/guidelines/. [Accessed 14 May 2024]
Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 2011; 89:662–673.
National Library of Medicine, National Center for Biotechnology Information. GTR: Genetic Testing Registry. https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=(testpurpose_drugresponse[PROP])&filter=testtype:clinical;certification:clia. [Accessed 16 May 2024]
Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, et al. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin Transl Sci 2017; 10:143–146.
Owen RP, Altman RB, Klein TE. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum Mutat 2008; 29:456–460.
Caudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM, Hoffman JM. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics 2018; 19:847–860.
Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet 2011; 12:69–73.
Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med 2019; 21:2255–2263.
Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, et al. Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 2018; 104:664–674.
Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, et al. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med 2021; 23:2335–2341.
Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, et al. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci 2022; 15:371–383.
Scott SA, Owusu Obeng A, Botton MR, Yang Y, Scott ER, Ellis SB, et al. Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. Pharmacogenomics 2017; 18:1381–1386.
Cavallari LH, Weitzel KW, Elsey AR, Liu X, Mosley SA, Smith DM, et al. Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics 2017; 18:421–426.
Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther 2017; 102:502–510.
Aquilante CL, Kao DP, Trinkley KE, Lin CT, Crooks KR, Hearst EC, et al. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics 2020; 21:375–386.
Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, et al. Integrating somatic and germline next-generation sequencing into routine clinical oncology practice. JCO Precis Oncol 2021; 5:884–895.
Shriver SP, Adams D, McKelvey BA, McCune JS, Miles D, Pratt VM, et al. Overcoming barriers to discovery and implementation of equitable pharmacogenomic testing in oncology. J Clin Oncol 2024; 42:1181–1192.
Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21:237–242.
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16:1639–1650.
Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 2021; 26:1008–1016.
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, et al. DPYD testing: time to put patient safety first. J Clin Oncol 2023; 41:2701–2705.
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018; 103:210–216.
Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 2020; 28:508–517.
Knikman JE, Wilting TA, Lopez-Yurda M, Henricks LM, Lunenburg C, de Man FM, et al. Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy—a matched-pair analysis. J Clin Oncol 2023; 41:5411–5421.
Henricks LM, Lunenburg C, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018; 19:1459–1467.
de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, et al. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 2023; 8:101197.
Cascorbi IW. Is there still debate about recommending DPYD-testing before fluoropyrimidine treatment? Clin Pharmacol Ther 2023; 114:733–737.
FDA. Project Renewal; 2023. https://www.fda.gov/about-fda/oncology-center-excellence/project-renewal. [Accessed 14 May 2024]
Hertz DL, Smith DM, Scott SA, Patel JN, Hicks JK. Response to the FDA decision regarding DPYD testing prior to fluoropyrimidine chemotherapy. Clin Pharmacol Ther 2023; 114:768–779.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Cancer (V.1.2024) and Colon Cancer V.1.2024. www.nccn.org. [Accessed 27 February 2024]
Precision Medicine Online. Cancer centers nudge oncologists toward DPYD testing as PGx supporters push for guidelines change. https://www.precisionmedicineonline.com/regulatory-news-fda-approvals/cancer-centers-nudge-oncologists-toward-dpyd-testing-pgx-supporters. [Accessed 14 May 2024]
Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, et al. UGT1A1 guided cancer therapy: review of the evidence and considerations for clinical implementation. Cancers (Basel) 2021; 13:1566.
Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet 2023; 31:982–987.
Karas S, Innocenti F. All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide. JCO Oncol Pract 2022; 18:270–277.
Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RHN, Schwab M, et al. Global pharmacogenomics within precision medicine: challenges and opportunities. Clin Pharmacol Ther 2020; 107:57–61.
Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, et al. Integrating genomics into healthcare: a global responsibility. Am J Hum Genet 2019; 104:13–20.
Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry Zgheib N. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. Br J Clin Pharmacol 2019; 85:2076–2088.
Bastaki K, Velayutham D, Irfan A, Adnan M, Mohammed S, Mbarek H, et al. Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives. Front Public Health 2024; 12:1364221.
Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. Advancing CYP2D6 pharmacogenetics through a pharmacoequity lens. Clin Pharmacol Ther 2023; 114:69–76.
Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving pharmacogenetics into practice: it’s all about the evidence! Clin Pharmacol Ther 2021; 110:649–661.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 2023; 401:347–356.
Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine 2024; 101:105009.
Jarvis JP, Peter AP, Keogh M, Baldasare V, Beanland GM, Wilkerson ZT, et al. Real-world impact of a pharmacogenomics-enriched comprehensive medication management program. J Pers Med 2022; 12:421.
Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid 2010; 20:681–687.
Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. [Accessed 10 April 2024]
Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J 2015; 15:201–210.
American Society of Pharmacovigilance. STRIPE Collaborative Community. https://www.stopadr.org/stripe. [Accessed 8 July 2024]
Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, Weck KE. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn 2018; 20:269–276.
European Medicines Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine. [Accessed 4 December 2024].
Hertz DL, Bousman CA, McLeod HL, Monte AA, Voora D, Orlando LA, et al. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. Am J Health Syst Pharm 2024; 81:672–683.
Pierson B. Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million. Vol. 2024. Reuters, 2024.
Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89:464–467.
Leitch TM, Killam SR, Brown KE, Katseanes KC, George KM, Schwanke C, et al. Ensuring equity: pharmacogenetic implementation in rural and tribal communities. Front Pharmacol 2022; 13:953142.
Dorfman EH, Brown Trinidad S, Morales CT, Howlett K, Burke W, Woodahl EL. Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics 2015; 16:227–237.
Fatumo S, Chikowore T, Choudhury A, Ayub M, Martin AR, Kuchenbaecker K. A roadmap to increase diversity in genomic studies. Nat Med 2022; 28:243–250.
Tang Girdwood SC, Rossow KM, Van Driest SL, Ramsey LB. Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatr Res 2022; 91:529–538.
Lin GA, Coffman JM, Phillips KA. The state of state biomarker testing insurance coverage laws. JAMA 2024; 331:1885–1886.
Morris SA, Alsaidi AT, Verbyla A, Cruz A, Macfarlane C, Bauer J, Patel JN. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther 2022; 112:1318–1328.
Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. PharmacoEcon 2004; 22:857–876.
Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990–2021. JAMA 2023; 329:1312–1314.
Reckers-Droog VT, van Exel NJA, Brouwer WBF. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Policy 2018; 122:621–629.
Food and Drug Administration. Webinar – final rule: medical devices; laboratory developed tests. https://www.fda.gov/medical-devices/medical-devices-news-and-events/webinar-final-rule-medical-devices-laboratory-developed-tests-05142024#:~:text=On%20April%2029%2C%202024%2C%20the,the%20IVD%20is%20a%20laboratory. [Accessed 26 June 2024]
Pereira NL, Cresci S, Angiolillo DJ, Batchelor W, Capers Q, Cavallari LH, et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation 2024; 150:e129–e150.
Beitelshees AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, et al. CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings. J Am Heart Assoc 2022; 11:e024159.

Auteurs

Larisa H Cavallari (LH)

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville.

J Kevin Hicks (JK)

Department of Pathology, Moffitt Cancer Center, Tampa, Florida.

Jai N Patel (JN)

Atrium Health Levine Cancer Institute, Charlotte.
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.

Amanda L Elchynski (AL)

Department of Pharmacy, Arkansas Children's Hospital, Little Rock, Arkansas.

D Max Smith (DM)

MedStar Health, Columbia, Maryland.
Department of Oncology, Georgetown University Medical Center, Washington, DC.

Salma A Bargal (SA)

Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

Ashley Fleck (A)

Department of Pharmacy, Richard L. Roudebush Veterans Affairs Medical Center, Veteran Health Indiana, Indianapolis, Indiana.

Christina L Aquilante (CL)

Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado.
Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Shayna R Killam (SR)

L.S. Skaggs Institute for Health Innovation and Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana.

Lauren Lemke (L)

Lifespan, Providence, Rhode Island, USA.

Taichi Ochi (T)

Department of Pharmacotherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy; and University Library, University of Groningen, Groningen, The Netherlands.

Laura B Ramsey (LB)

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri.

Cyrine E Haidar (CE)

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.

Teresa Ho (T)

Department of Pathology, Moffitt Cancer Center, Tampa, Florida.

Nihal El Rouby (N)

Department of Pharmacy, St. Elizabeth HealthCare, Edgewood, Kentucky.
Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio.

Andrew A Monte (AA)

Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, Colorado.
University of Colorado School of Medicine, Aurora, Colorado.

Josiah D Allen (JD)

Department of Pharmacy, St. Elizabeth HealthCare, Edgewood, Kentucky.

Amber L Beitelshees (AL)

Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

Jeffrey R Bishop (JR)

Department of Experimental and Clinical Pharmacology and Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota, USA.

Chad Bousman (C)

Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.

Ronald Campbell (R)

Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania.

Emily J Cicali (EJ)

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville.

Kelsey J Cook (KJ)

Department of Pharmacy Education and Practice, University of Florida College of Pharmacy.
Nemours Children's Health, Jacksonville, Florida.

Benjamin Duong (B)

Precision Medicine Program, Nemours Children's Health Delaware Valley, Wilmington, Delaware, USA.

Evangelia Eirini Tsermpini (EE)

Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Sonya Tang Girdwood (ST)

Divisions of Hospital Medicine and Translational and Clinical Pharmacology, Cincinnati Children's Hospital.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

David B Gregornik (DB)

Pharmacogenomics Program, Children's Minnesota, Minneapolis/St Paul, Minnesota.

Kristin N Grimsrud (KN)

Department of Pathology and Laboratory Medicine, University of California Health, Sacramento, California.

Nathan Lamb (N)

Department of Pharmacy, Ann & Robert H. Lurie Children's Hospital of Chicago.

James C Lee (JC)

Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.

Rocio Ortiz Lopez (RO)

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, Mexico.

Tinashe Adrian Mazhindu (TA)

African Institute of Biomedical Sciences & Technology, Harare, Zimbabwe.

Sarah A Morris (SA)

Atrium Health Levine Cancer Institute, Charlotte.
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.

Mohamed Nagy (M)

Personalised Medication Management Unit, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.

Jenny Nguyen (J)

Personalized Care Program, Children's Hospital Los Angeles, Los Angeles, California.

Amy L Pasternak (AL)

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan.

Natasha Petry (N)

Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota.
Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota, USA.

Ron H N van Schaik (RHN)

Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

April Schultz (A)

Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota.
Department of Internal Medicine, University of South Dakota School of Medicine, Vermillion, South Dakota.

Todd C Skaar (TC)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Hana Al Alshaykh (H)

Pharmaceutical Care Department, King Faisal Specialist Hospital and Research Center, College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.

James M Stevenson (JM)

Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Rachael M Stone (RM)

Department of Pharmacy, University of Virginia, Charlottesville, Virginia.

Nam K Tran (NK)

Department of Pathology and Laboratory Medicine, University of California Health, Sacramento, California.

Sony Tuteja (S)

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Erica L Woodahl (EL)

L.S. Skaggs Institute for Health Innovation and Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana.

Li-Chi Yuan (LC)

Providence Health and Services, Irvine, California and.

Craig R Lee (CR)

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Classifications MeSH